Algynomics

Algynomics was a biotechnology company specializing in the pharmacogenetics of pain and the development of personalized medicine solutions. Founded as a spin-out from the University of North Carolina at Chapel Hill, the company leveraged proprietary genetic research to identify biomarkers associated with pain sensitivity and analgesic response. Their core technology, the PainGene platform, aimed to assist pharmaceutical companies in patient stratification for clinical trials and to help clinicians tailor pain management strategies. Algynomics focused on genetic targets such as Catechol-O-methyltransferase (COMT) and GTP cyclohydrolase 1 (GCH1) to address conditions like chronic pain and temporomandibular disorders. The company operated as a contract research organization and diagnostic provider until its acquisition by Bio-Rad Laboratories in 2012.